NeOnc Technologies Holdings is trading 6.16% down at $4.34 after profit-taking and broader biotech weakness.
- The biotech sector is down 2.47%, contributing to today’s decline.
- Positive Phase 2a NEO100 results reported 48.9% six-month progression-free survival versus a 20% historical benchmark, helping drive substantial gains earlier this week.
- No new company-specific negative announcement appears to be driving the move.